Myriad Genetics's total assets for Q1 2026 were $673.70M, a decrease of -4.66% from the previous quarter. MYGN total liabilities were $336.30M for the fiscal quarter, a -0.68% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.